Synpromics appoints Dr John Shields as Investor Director and Dr Ken Macnamara as Director of Operations.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy.
Synthetic promoters to be developed for gene therapy in eye disease.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.
Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.